Sofinnova Investments’s BioCryst Pharmaceuticals BCRX Stock Holding History

Sofinnova Investments’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,510,473	Closed	-$20.9M	–	67
2021 Q4	$20.9M	Buy	+1,510,473	New	+$20M	1.22%	23
2021 Q3	–	Sell	-158,609	Closed	-$2.51M	–	75
2021 Q2	$2.51M	Sell	158,609 -220,165	-58%	-$2.99M	0.14%	60
2021 Q1	$3.85M	Sell	378,774 -744,026	-66%	-$7.67M	0.23%	56
2020 Q4	$8.37M	Buy	1,122,800 +329,746	+42%	+$1.7M	0.5%	39
2020 Q3	$2.73M	Sell	793,054 -564,794	-42%	-$2.42M	0.2%	56
2020 Q2	$6.47M	Buy	1,357,848 +542,158	+66%	+$2.17M	0.41%	46
2020 Q1	$1.63M	Sell	815,690 -1,335,474	-62%	-$3.68M	0.15%	56
2019 Q4	$7.42M	Buy	2,151,164 +1,634,430	+316%	+$4.11M	0.53%	39
2019 Q3	$1.48M	Buy	516,734 +90,334	+21%	+$281K	0.13%	65
2019 Q2	$1.62M	Buy	+426,400	New	+$2.57M	0.15%	63

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sofinnova Investments's BCRX Position: Q1 2022 in Review

Sofinnova Investments sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2022, closing a stake of 1,510,473 shares — an estimated $20.9M sold.

Sofinnova Investments first reported a position in BCRX in Q2 2019 and held it in 10 quarters. The position peaked at $20.9M in Q4 2021. 233 funds tracked by Wall St. Rank hold BCRX as of Q1 2022.

Sofinnova Investments reported no remaining BioCryst Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Sofinnova Investments sold 1,510,473 BioCryst Pharmaceuticals shares in Q1 2022, an estimated $20.9M.
Sofinnova Investments first reported a position in BioCryst Pharmaceuticals in Q2 2019 and held it in 10 quarters.
Sofinnova Investments's BioCryst Pharmaceuticals position peaked at $20.9M in Q4 2021.
233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2022.

Based on Sofinnova Investments's 13F filing for Q1 2022, filed 16 May 2022.